Figure 2: The four keys to success for radiosensitizers in brain metastases, which historically have been characterized by a paucity of viable therapeutic options due to an inability to overcome at least four treatment hurdles. In theory these keys or criteria for success in brain metastases are met by RRx- 001 and 2-DG.